IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1. (currently amended) A method for ~~**preventing or**~~ treating a condition associated with cortical spreading depression (CSD) in a subject, comprising administering to the subject, in an amount effective to suppress CSD, a compound having the Formula (IIb)



Formula (IIb)

wherein

Ar is phenyl which is unsubstituted or substituted with at least one halo group;

R_3 is CH_2–Q, wherein Q is lower alkoxy containing 1–3 carbon atoms; and

R_1 is lower alkyl containing 1–3 carbon atoms,

or a pharmaceutically acceptable salt thereof**, wherein the condition associated with CSD is a chronic headache selected from a group consisting of a muscle contraction headache, a toxic headache, a cluster headache, a traction headache, and an inflammatory headache**.

2.-13. (cancelled)

14. (previously presented) The method of claim 1, wherein the compound is

(R)-2-acetamido-N-benzyl-3-methoxypropionamide;

O-methyl-N-acetyl-D-serine-m-fluorobenzylamide; or

O-methyl-N-acetyl-D-serine-p-fluorobenzylamide.

15. (cancelled).

16. (previously presented) The method of claim 1 wherein, in the compound of Formula (IIb), Ar is unsubstituted phenyl.

17. (withdrawn - previously presented) The method of claim 1 wherein, in the compound of Formula (IIb), halo is fluoro.

18. (previously presented) The method of claim 1 wherein, in the compound of Formula (IIb), R_3 is CH_2–Q, wherein Q is alkoxy containing 1–3 carbon atoms and Ar is unsubstituted phenyl.

19. (cancelled)

20. (previously presented) The method of claim 1, wherein the compound is substantially enantiopure.

21-23. (cancelled)

24. (currently amended) The method of claim 1, wherein the compound of Formula (IIb) is (R)-2-acetamido-N-benzyl-3-methoxypropionamide ~~**or a pharmaceutically acceptable salt thereof**~~.

25. (previously presented) The method of claim 24, wherein the compound is substantially enantiopure.

26. (previously presented) The method of claim 1, wherein the compound is administered at a dose of at least 100 mg/day.

27. (currently amended) The method of claim 1, wherein the compound is administered at a dose of at a maximum ~~**[[6]]**~~ **1** g/day.

28. (previously presented) The method of claim 1, wherein the compound is administered at increasing daily doses until a predetermined daily dose is reached which is maintained during further treatment.

29. (previously presented) The method of claim 1, wherein the compound is administered in at most three doses per day.

30. (previously presented) The method of claim 1, wherein administration of the compound results in a plasma concentration of 7 to 8 μg/ml (trough) and 9 to 12 μg/ml (peak).

31. (previously presented) The method of claim 1, wherein the compound is administered for at least one week.

32. (previously presented) The method of claim 1, wherein the compound is administered orally.

33. (currently amended) The method of claim 1, further comprising administering to the subject a further active agent effective for prevention or treatment of a headache or a CSD-associated ~~**disorder**~~ **condition**.

34. (previously presented) The method of claim 33, wherein the compound of Formula (IIb) and the further active agent are present in a single dose form.

35. (previously presented) The method of claim 1, wherein the subject is a mammal.

36. (previously presented) The method of claim 35, wherein the subject is human.

37. (previously presented) A therapeutic combination comprising

    (a) a compound of Formula (IIb), and

    (b) a further active agent effective for prevention or treatment of a headache or a CSD-associated disorder.

38. (previously presented) The combination of claim 37, wherein the compound of Formula (IIb) and the further active agent are present in a single dose form.

39. (previously presented) The combination of claim 37, wherein the compound of Formula (IIb) and the further active agent are present in separate dose forms.

40. (previously presented) The method of claim 33, wherein the compound of Formula (IIb) and the further active agent are present in separate dose forms.

41. (cancelled)

42. (previously presented) The method of claim 1, wherein the compound is administered at a dose of at a maximum 1 g/day.

43. (previously presented) The method of claim 1, wherein the compound is administered at a dose of at a maximum 400 mg/day.

44. (cancelled)

45. (cancelled)

46. (currently amended) A method of **suppressing CSD to** prevent~~[[ing]]~~ or treat~~[[ing]]~~ a headache selected from the group consisting of a muscle contraction headache, a toxic headache, a cluster headache, a traction headache, ~~[[or]]~~ **and** an inflammatory headache, the method comprising

administering to the subject an oral effective amount of (R)-2-acetamido-N-benzyl-3-methoxypropionamide.

47. (previously presented) The method of claim 46, wherein the headache is cluster headache.

48. (currently amended) The method of any one of Claims ~~[[44]]~~ **46** to 47, further comprising administering to the subject a triptan.

49. (previously presented) The method of claim 48, wherein the triptan is sumatriptan.

50. (previously presented) The combination of claim 37, wherein the compound of Formula IIb is (R)-2-acetamido-N-benzyl-3-methoxypropionamide.

51. (previously presented) The combination of claim 37, wherein the further active agent effective for prevention or treatment of a headache or a CSD-associated disorder is a triptan.

52. (previously presented) A method of suppressing CSD in a subject, the method comprising orally administering to the subject about 100 mg/day to about 400 mg/day (R)-2-acetamido-N-benzyl-3-methoxypropionamide.

53. (new) The method of claim 33, wherein the further active agent is effective for treatment of a CSD-associated condition selected from the group consisting of head injury, transient global amnesia, and intracranial hemorrhage.

54. (new) The method of claim 52, wherein suppressing CSD prevents or treats a chronic headache selected from a group consisting of a muscle contraction headache, a toxic headache, a cluster headache, a traction headache, and an inflammatory headache.

55. (new - withdrawn) A method of treating a CSD-associated condition selected from the group consisting of a head injury, transient global amnesia, and intracranial hemorrhage, the method comprising administering to the subject an effective amount of (R)-2-acetamido-N-benzyl-3-methoxypropionamide.